

IntelGenx Technologies Corp.  
Form 8-K  
April 07, 2008

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934

**April 7, 2008**  
Date of Report (Date of earliest event reported)

---

**INTELGEXX TECHNOLOGIES CORP.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**

(State or other jurisdiction  
of incorporation)

**000-31187**

(Commission File No.)

**87-0638336**

(IRS Employer ID)

**6425 Abrams, Ville Saint Laurent, Quebec, H4S 1X9 Canada**

(Address of principal executive offices and Zip Code)

**(514) 331-7440**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- £ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - £ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - £ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - £ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 1.01 Entry into a Material Definitive Agreement.

IntelGenx Corp. (OTCBB:IGXT) ("IntelGenx") and Cary Pharmaceuticals ("Cary") today ratified the Definitive Agreement ("Agreement") originally signed on November 5, 2007 to jointly develop and commercialize Cary's oral antidepressant ("*CPI-300*" or the "Product") using IntelGenx's proprietary oral delivery technology.

Under the terms of the Agreement, IntelGenx will provide funding and development support for the Product and will be entitled to profit sharing. The parties anticipate that a New Drug Application ("NDA") will be filed with the United States Food and Drug Administration ("FDA") during the second half of 2008. Commercial launch of the Product is expected upon FDA approval in 2009.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits

<u>Exhibit</u>	<u>Description</u>
<u>99.1</u>	<u>Press Release</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**INTELGENX TECHNOLOGIES CORP.**

By: /s/ Horst Zerbe  
Horst Zerbe  
President and Chief  
Executive Officer

Date: April 7, 2008